



Cite this: *Chem. Commun.*, 2022, 58, 3071

DOI: 10.1039/d2cc90072f

rsc.li/chemcomm

## Correction: <sup>19</sup>F-Tagged metal binding pharmacophores for NMR screening of metalloenzymes

Kathleen E. Prosser, Alysia J. Kohlbrand, Hyeonglim Seo, Mark Kalaj and Seth M. Cohen\*

Correction for ' <sup>19</sup>F-Tagged metal binding pharmacophores for NMR screening of metalloenzymes' by Kathleen E. Prosser *et al.*, *Chem. Commun.*, 2021, **57**, 4934–4937, DOI: 10.1039/D1CC01231B.

The authors regret that the Conflicts of Interest statement in the original manuscript was incomplete. The full Conflicts of Interest statement is as follows:

S. M. C. is a cofounder of and has an equity interest in Cleave Therapeutics, Forge Therapeutics, and Blacksmith Medicines, companies that may potentially benefit from the research results. S. M. C. also serves on the Scientific Advisory Board for Blacksmith Medicines and serves on the Scientific Advisory Board and receives compensation from Forge Therapeutics. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

